PRESS RELEASE
News
-
-
REGULATED PRESS RELEASE
Mersen: Number of shares and voting rights as of December 31, 2023
This press release discloses the total number of voting rights and shares in the capital of Mersen pursuant to French regulations. As of December 31, 2023, the company has 24,418,312 shares and a total of 27,074,432 theoretical voting rights, excluding shares deprived of voting rights. Mersen is a global expert in electrical specialties and advanced materials, with a presence in 34 countries and listed on Euronext Paris. -
REGULATED PRESS RELEASE
Mersen : Nombre d'actions et de droits de vote au 31 décembre 2023
Mersen déclare le nombre d'actions et de droits de vote au 31 décembre 2023. Expert mondial des spécialités électriques et des matériaux avancés pour les industries High-Tech. Coté sur le Compartiment B d’Euronext -
REGULATED PRESS RELEASE
Groupe DLSI - Nouvelles acquisitions 2024
Le Groupe DLSI annonce l'acquisition de ML Intérim et PRESTIM, renforçant sa présence dans le Grand Est et confirmant ses ambitions de devenir un acteur majeur de l'intérim dans la région. Le chiffre d'affaires du 4ème trimestre sera publié le 16 février 2024 -
PRESS RELEASE
Truemed and NASM Partner for Tax-Free HSA/FSA Spending for Personal Training
The partnership between Truemed and NASM allows personal trainers to offer clients the opportunity to use their HSA/FSA funds to pay for their personal training expenses, potentially leading to significant savings for clients. This unique collaboration aims to help personal trainers expand their client base, increase revenue, and enhance their credibility, while also making the process seamless for clients. NASM-certified trainers can enroll in the program at no cost, and Truemed provides all the necessary information for clients to get started. The initiative, designed to support overall health, involves an independent medical provider determining client eligibility for HSA/FSA funding and issuing a Letter of Medical Necessity for tax-free payment of fitness and wellness professional fees. For more information, visit Truemed.com and NASM.org. -
PRESS RELEASE
Quantas Labs Secures $550K in Seed Funding to Propel AI-Driven Erosion Impact Forecasting Technology
Quantas Labs, the pioneering force behind the world's first commercial AI for erosion impact prediction, has successfully closed a $550K seed funding round. Led by founder Alex Pourquery, the London-based company aims to deliver cutting-edge erosion forecasting solutions vital for sustainable land management. Their proprietary technology combines advanced hybrid AI framework, real-time data integration, advanced soil type classification, and robust data handling to revolutionize erosion impact prediction. The seed funding will significantly boost development and go-to-market strategies, accelerating their path to becoming a leader in geotechnical analysis. -
PRESS RELEASE
Torq Raises C$5.3M in Concurrent Offerings
Torq Resources Inc. completed a concurrent public and private offering of equity securities, issuing 23,206,860 units at a price of C$0.23 per unit. Gold Fields increased its ownership of Torq to 15.48% through a concurrent private placement. The proceeds will be used for exploration at Torq's Santa Cecilia gold-copper project in Chile and for general corporate and working capital purposes. Paradigm Capital Inc. and Red Cloud Securities Inc. acted as co-lead agents for the public offering, with Beacon Securities Limited as a member of the syndicate of agents. -
PRESS RELEASE
Canada Jetlines Expands Fleet with Leasing of Two Fuel-Efficient A320-214 Aircraft
Canada Jetlines Operations Ltd. is proud to announce the addition of two new A320-214 aircraft to its fleet, as part of a strategic move to meet the growing demand for affordable air travel. The A320-214 aircraft, scheduled for delivery in Q2 of 2024, will enhance Canada Jetlines' operational capabilities and contribute to the expansion of its fleet size in the coming year. The addition of these aircraft aligns with the company's mission to provide reliable and cost-effective travel options for travelers, while maintaining its commitment to safety and service excellence. -
PRESS RELEASE
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
Edesa Biotech, Inc. (Nasdaq:EDSA) will be participating in the 2024 Dermatology Summit on January 7, 2024, and in one-on-one meetings alongside the J.P. Morgan 42nd Annual Healthcare Conference from January 8-11, 2024 in San Fransico, California. Attendees interested in meeting with management can request meetings by contacting Edesa at investors@edesabiotech.com. Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases. The company is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), and has also received regulatory approval to conduct a Phase 2 trial of its EB06 monoclonal antibody as a treatment for vitiligo. Additionally, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD) and is planning a future Phase 2 study of paridiprubart for fibrotic diseases. For more information, contact Gary Koppenjan at (289) 800-9600 or investors@edesabiotech.com. -
PRESS RELEASE
US$1,179/tonne in Sales to Date Indicate Initial In-Situ Realized Contained Jade Value at Jade Leader's Sky Zone, Wyoming
Jade Leader Corp. (TSX.V:JADE) provides a corporate, marketing, and exploration update, showcasing increasing sales in 2023 and the successful marketing efforts to raise international awareness of their Wyoming and Washington jades. The company's research has led to the recognition of Sky Jades© as Earth's first jades. With ongoing jade sales and marketing expansion, Jade Leader Corp. continues to grow its online presence and add finished products to its inventory. The publication of their research article in Gem-A's The Journal of Gemmology is expected to boost the company's visibility in the international gem community.
